Close this search box.

Study of COVID-19 survivors’ profiles
for detection of ME/CFS (SCOPIMED)

The purpose of this study is to capture a post-COVID-19 infected population willing to participate in phenotyping studies early in the post-COVID-19 illness progression, with an aim of providing targeted effective therapies and preventing the onset and progression of ME/CFS.

  • Alain Moreau, PhD

Development of an algorithm using our 11 microRNA diagnostic panel allowing the stratification of long COVID patients along different long-term sequelae trajectories:

  • ME/CFS, ME/CFS + FM or FM
  • Severe respiratory dysfunction
  • Neurological
  • Allergy-related.

BrainCheck neurocognitive evaluations prior and after the induction of PEM led us to stratify long COVID patients into four clusters using a machine-learning method.

  • Patients classified in cluster A and B exhibit a neurocognitive profile often seen in ME/CFS patients while long COVID patients in cluster C and D exhibit more often neurological sequelae.
  • Preliminary findings suggest that long COVID patients in cluster B exhibit a better recovery of their neurocognitive function than those in cluster A or C 
  • Next Steps: Validate these findings in a larger cohort. 


The development of ME/CFS and related conditions like fibromyalgia (FM) among a subset of COVID-19 long-haulers is thought to be the result of a broad molecular-level reorganization occurring at the epigenetic level, which drives the host response following SARS-CoV-2 viral infection.

While ME/CFS researchers understand that many factors likely contribute to the onset of the condition, it is important to identify the risks of ME/CFS sequelae as early as possible. Studying the post-COVID-19 infected population may offer insight that helps ME/CFS patients by expanded understanding of the progression of the condition and identifying targeted treatment strategies. Finally, the study of COVID-19 long-haulers may shed light on ME/CFS and post-infectious fatigue syndrome following infections other than COVID-19.



  • Recruit a cohort of 50 COVID-19 long haulers.
  • Conduct a study of the global circulating microRNA expression profiles. 
  • Perform global DNA methylation profiling.
  • Conduct epigenome-wide association analysis.
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669